{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-010656","form_type":"8-K/A","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2026-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.700171+00:00","generated_at":"2026-05-15T09:22:17.600892+00:00","sec_items":["1.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments","bullets":["Settlement resolves all US and international patent infringement litigation between Genevant/Arbutus and Moderna over LNP technology in COVID-19 and other mRNA vaccines.","Moderna receives broad license to Genevant/Arbutus patent rights for defined Moderna Licensed Products, including SPIKEVAX, mNEXSPIKE, mRESVIA, and certain other mRNA vaccines.","Moderna will make a noncontingent lump-sum payment (amount redacted) and a contingent payment tied to the outcome of Moderna's appeal on the §1498 government-contractor defense.","Parties stipulate to dismissal of US and ex-US litigation with prejudice; Moderna retains right to appeal only on the §1498 Disputed Matter.","Moderna agrees not to challenge validity/enforceability of specified patents owned by Genevant/Arbutus."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-010656","json":"https://secwatch.observer/filing/0001140361-26-010656.json","markdown":"https://secwatch.observer/filing/0001140361-26-010656.md","text":"https://secwatch.observer/filing/0001140361-26-010656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/ef20068452_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:22:17.600892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40d7e8acc138e510c070e5758de838bfde1a59d3","claim":"Roivant Sciences Ltd. entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. (together, \"Moderna\") (effective 2026-03-03).","evidence_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001437749-26-014906","ticker":"SGRP","company_name":"SPAR Group, Inc.","filed_at":"2026-05-05T23:59:59+00:00","headline":"SPAR Group settles arbitration with founder Robert Brown; extends CIC agreement to 2028","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-014906","json":"https://secwatch.observer/filing/0001437749-26-014906.json","markdown":"https://secwatch.observer/filing/0001437749-26-014906.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/sgrp20260505_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On May 1, 2026, the Company entered into a Settlement Agreement and Release with Robert G. Brown and SPAR Business Services, Inc. allowing for a dismissal of the Arbitration action between the Company and Robert G. Brown.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1004989/000143774926014906/0001437749-26-014906-index.htm"}},{"accession":"0001628280-26-027280","ticker":"OPY","company_name":"OPPENHEIMER HOLDINGS INC","filed_at":"2026-04-27T23:59:59+00:00","headline":"Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-027280","json":"https://secwatch.observer/filing/0001628280-26-027280.json","markdown":"https://secwatch.observer/filing/0001628280-26-027280.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/opy-20260424.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On April 24, 2026, Oppenheimer & Co., Inc. (“Oppenheimer”), the principal operating subsidiary of Oppenheimer Holdings Inc. (the “Company”), reached an agreement to settle the previously disclosed litigation styled Liberty Capital Group, Individually and on Behalf of All Others Similarly Situated v. Oppenheimer Holdings Inc., Oppenheimer & Co. Inc., and Oppenheimer Asset Management Inc. , No. 1:25-cv04822-JSR which was filed in the United States District Court for the Southern District of New York in June of 2025 (the “ District Court”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/791963/000162828026027280/0001628280-26-027280-index.htm"}},{"accession":"0001805651-26-000038","ticker":"MKTW","company_name":"MARKETWISE, INC.","filed_at":"2026-04-24T23:59:59+00:00","headline":"MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights","event_type":"litigation","sec_items":["1.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001805651-26-000038","json":"https://secwatch.observer/filing/0001805651-26-000038.json","markdown":"https://secwatch.observer/filing/0001805651-26-000038.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/mktw-20260421.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On April 21, 2026, Marketwise, Inc. (the “Company”) and its subsidiary, MarketWise, LLC (together with the Company, “MarketWise”), entered into a Settlement Agreement and Release (the “Settlement Agreement”) with Mark P. Arnold, the Company’s former Chief Executive Officer, and JAMA 2021, LLC (together with Mr. Arnold, the “Arnold Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1805651/000180565126000038/0001805651-26-000038-index.htm"}},{"accession":"0001171843-26-002591","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-04-21T23:59:59+00:00","headline":"Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment","event_type":"litigation","sec_items":["1.01","5.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002591","json":"https://secwatch.observer/filing/0001171843-26-002591.json","markdown":"https://secwatch.observer/filing/0001171843-26-002591.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/f8k_042026.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On April 10, 2026, Allied Gaming & Entertainment Inc. (the “Company”) and Yangyang Li, its Chief Executive Officer and Chairman, in his personal capacity (“Mr. Li”, and together with the Company, the “Allied Parties”) entered into a binding Term Sheet for Global Resolution (the “Term Sheet”) with Knighted Pastures, LLC (“Knighted”) and Roy Choi, in his personal capacity (“Mr. Choi”, and together with Knighted, the “Knighted Parties”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000117184326002591/0001171843-26-002591-index.htm"}},{"accession":"0001193125-26-117652","ticker":"OESX","company_name":"ORION ENERGY SYSTEMS, INC.","filed_at":"2026-03-20T23:59:59+00:00","headline":"Orion settles Voltrek earnout dispute for $3M cash; solar PPA exit adds $1.3M offset","event_type":"litigation","sec_items":["1.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-117652","json":"https://secwatch.observer/filing/0001193125-26-117652.json","markdown":"https://secwatch.observer/filing/0001193125-26-117652.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/0001193125-26-117652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/oesx-20260317.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On March 17, 2026, Orion Energy Systems, Inc. and its subsidiaries (collectively, the “ Company ”) entered into a settlement agreement (the “ Settlement Agreement ”) with Final Frontier, LLC (“ Final Frontier ”) and Kathleen M. Connors (“ Ms. Connors ”), personally and as Trustee of the Kathleen M. Connors 2019 Revocable Trust","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1409375/000119312526117652/0001193125-26-117652-index.htm"}},{"accession":"0001193125-26-094084","ticker":"TRNR","company_name":"Interactive Strength, Inc.","filed_at":"2026-03-05T23:59:59+00:00","headline":"TRNR recovers $6.4M in full settlement of Sportstech loan dispute, ends legal proceedings","event_type":"litigation","sec_items":["1.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-094084","json":"https://secwatch.observer/filing/0001193125-26-094084.json","markdown":"https://secwatch.observer/filing/0001193125-26-094084.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785056/000119312526094084/0001193125-26-094084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785056/000119312526094084/trnr-20260227.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On February 27, 2026, the Company and Sportstech entered into a Settlement Agreement (the “Settlement Agreement”), pursuant to which Sportstech was to pay the Company $6,350,000 along with making a payment to the Company’s counsel in its legal dispute with Sportstech (the “Settlement Payment”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1785056/000119312526094084/0001193125-26-094084-index.htm"}},{"accession":"0001437749-26-015945","ticker":"ICCC","company_name":"IMMUCELL CORP /DE/","filed_at":"2026-05-08T23:59:59+00:00","headline":"ImmuCell settles Norbrook dispute, to receive $2M payment","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-015945","json":"https://secwatch.observer/filing/0001437749-26-015945.json","markdown":"https://secwatch.observer/filing/0001437749-26-015945.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/iccc20260508_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying 2019 Development Services and Commercial Supply Agreement between the two companies.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000143774926015945/0001437749-26-015945-index.htm"}},{"accession":"0001193125-26-157030","ticker":"MCHX","company_name":"MARCHEX INC","filed_at":"2026-04-15T23:59:59+00:00","headline":"Marchex settles civil lawsuit for $2M, payments spread over 13 months","event_type":"litigation","sec_items":["1.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01","same event type: litigation","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-157030","json":"https://secwatch.observer/filing/0001193125-26-157030.json","markdown":"https://secwatch.observer/filing/0001193125-26-157030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/mchx-20260414.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm","comparable_excerpt":"On April 14, 2026, the Company entered into a Settlement Agreement (the “Agreement”) with respect to this civil action for such expected settlement amount, which resolves all claims related to this matter.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1224133/000119312526157030/0001193125-26-157030-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}